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Patients with cardiovascular disease display enhanced platelet activity, resulting in a prothrombotic state of the 
vasculature, and an increased susceptibility to (recurrent) car-
diovascular events.1 However, platelet activity not only figures 
thrombosis and hemostasis but also transforms the platelet 
into a protagonist of inflammation, and thereby a driver of ath-
erosclerosis.2 On activation and consequent granule release, 
platelets enrich the inflammatory milieu, activate the endo-
thelium, and promote leukocyte recruitment. Platelet-derived 
chemokines (eg, chemokine (C-C motif) ligand 5, chemo-
kine (C-C motif) ligand 2, and chemokine (C-X-C motif) 
ligand 4) stimulate the recruitment of leukocytes, whereas 
platelet-secreted mediators, such as soluble cluster of dif-
ferentiation (CD) 40L (sCD40L), serotonin, interleukin-1β 
(IL-1β), can activate endothelial cells (ECs) and leukocytes.3–7 
In parallel to the release of inflammatory mediators, platelets 
express a broad range of surface molecules that mediate plate-
let–leukocyte and platelet–endothelium interactions, includ-
ing P-selectin,8 glycoproteins (GP Ibα, GP VI, and αIIbβ3),9,10 
toll-like receptors (eg, toll-like receptor-2 and toll-like recep-
tor-4),11 and costimulatory molecules.2,4,12,13
Costimulatory molecules are originally known for their role 
as key mediators fine-tuning the adaptive immune response. 
Although the expression was classically ascribed to lymphocytes 
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Objective—Beyond their eminent role in hemostasis and thrombosis, platelets are recognized as mediators of inflammation. 
Platelet cluster of differentiation 40 (CD40) ligand (CD40L and CD154) plays a key role in mediating platelet-induced 
inflammation in atherosclerosis. CD40, the receptor for CD40L, is present on platelets; however, the role of CD40 on this 
cell type is until now undefined.
Approach and Results—We found that in both mice and humans, platelet CD40 mediates the formation of platelet–
leukocyte aggregates and the release of chemokine (C-X-C motif) ligand 4. Leukocytes were also less prone to adhere to 
CD40-deficient thrombi. However, platelet CD40 was not involved in platelet aggregation. Activated platelets isolated 
from Cd40−/−Apoe−/− mice adhered less to the endothelium upon injection into Apoe−/− mice when compared with CD40-
sufficient platelets. Furthermore, lack of CD40 on injected platelets led to reduced leukocyte recruitment to the carotid 
artery as assayed by intravital microscopy. This was accompanied by a decrease in endothelial vascular cell adhesion 
molecule-1, platelet endothelial cell adhesion molecule, VE-cadherin, and P-selectin expression. To investigate the 
effect of platelet CD40 in atherosclerosis, Apoe−/− mice received thrombin-activated Apoe−/− or Cd40−/−Apoe−/− platelets 
every 5 days for 12 weeks, starting at the age of 17 weeks, when atherosclerotic plaques had already formed. When 
compared with mice that received Apoe−/− platelets, those receiving Cd40−/−Apoe−/− platelets exhibited a >2-fold reduction 
in atherosclerosis. Plaques of mice receiving CD40-deficient platelets were less advanced, contained less macrophages, 
neutrophils, and collagen, and displayed smaller lipid cores.
Conclusions—Platelet CD40 plays a crucial role in inflammation by stimulating leukocyte activation and recruitment and 
activation of endothelial cells, thereby promoting atherosclerosis.  (Arterioscler Thromb Vasc Biol. 2016;36:482-490. 
DOI: 10.1161/ATVBAHA.115.307074.)
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and antigen-presenting cells, numerous studies demonstrated 
the presence of costimulatory molecules on a plethora of cell 
types, including platelets, thus implicating these cell types 
in the inflammatory process.14,15 An important costimulatory 
dyad in cardiovascular disease is CD40 and its ligand CD40L 
(CD154).14 Apolipoprotein E (Apoe−/−)– and Low-density lipo-
protein receptor (Ldlr−/−)–deficient mice exhibit a profound 
decrease in atherosclerosis when the CD40-CD40L signaling 
pathway is disrupted. In addition, these plaques contain few 
inflammatory cells and are rich in extracellular matrix.16–20
Both, CD40 and CD40L, are found in human atheroma and 
their expression increases with plaque progression.21 Upregulation 
of platelet CD40L predicts a poor clinical outcome after stroke,22 
and both platelet CD40L levels and monocyte CD40 levels are 
increased in hyperlipidemic patients.23 Moreover, serum lev-
els of sCD40L, a cleavage product of CD40L, associates with 
(recurrent) cardiovascular disease in many studies, such as the 
c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina 
(CAPTURE) trial,24 the Women’s health study,25 and others.26–28 
Although other clinical trials fail to show a correlation between 
sCD40L levels and cardiovascular disease29,30 and in an acute 
myocardial infarction model in humans,31 sCD40L is still corre-
lated with other biomarkers of inflammation.32 Moreover, deter-
mination of sCD40L in plasma is challenging, and differences in 
plasma preparation protocols might mask the validity of sCD40L 
as a biomarker in atherosclerosis.33–35
In mice, we have demonstrated that platelet CD40L plays 
a crucial role in initiation and progression of atherosclerosis by 
facilitating platelet–leukocyte aggregate formation and promot-
ing adherence of platelets and leukocytes to the endothelium.36 
However, platelets deficient in CD40L form less stable plate-
let aggregates37 and pose an increased risk for thromboembolic 
events.38 In addition, we recently showed that CD40L-deficient 
platelets prevent GP VI–dependent dense thrombus formation on 
collagen or atherosclerotic plaque material.39 Conversely, addition 
of CD40L enhanced GP VI–induced platelet aggregation via inte-
grin αIIbβ3 and phosphatidylinositol-4,5-bisphosphate 3-kinase, 
but independent of inhibitor of nuclear factor κ-B kinase subunit 
α/nuclear factor κ-light-chain-enhancer of activated B cells.39
Interestingly, platelets also express substantial levels of 
the alleged counter-receptor for CD40L, ie, CD40,40,41 but its 
role has only been summarily described and suggests a role 
in thrombus formation.37,39 Here, we report the participation 
of platelet CD40 in inflammation mediating EC and leuko-
cyte activation and driving atherosclerosis, whereas it plays a 
minor role in platelet–platelet interactions.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Deficiency of Platelet CD40 Does Not 
Impair Platelet Activation
To evaluate the effect of platelet CD40 deficiency on plate-
let activation, Cd40−/−Apoe−/− and Apoe−/− platelets were acti-
vated with different concentrations of thrombin, convulxin, 
and ADP, potent platelet receptor agonists. Corroborating 
our previous studies, no differences in P-selectin or αIIbβ3 
integrin activation were detected between Cd40−/−Apoe−/− and 
Apoe−/− platelets in any of the experimental conditions (Figure 
IA and IB in the online-only Data Supplement).39 In addi-
tion, collagen- or ADP-induced platelet aggregation in whole 
blood was not affected by deficiency of CD40 (Figure 1A and 
1B). However, supernatants of thrombin-activated platelets 
displayed a significant decrease in chemokine (C-X-C motif) 
ligand 4, identifying platelet CD40 as a prominent media-
tor of inflammation rather than a regulator of thrombosis 
(Figure 1C). Notably, platelets did not release IL-1β (Figure 
IC in the online-only Data Supplement).
Similar results were found in human platelets, in which 
CD40 was constitutively present and detectable on the surface 
on stimulation although overall expression level appeared low 
(Figure II in the online-only Data Supplement). When platelets 
were activated with an agonistic anti-CD40 antibody (clone 
G28.5) in combination with ADP or collagen, platelet aggre-
gation was unchanged (Figure IIIA in the online-only Data 
Supplement). Corroborating the results obtained with murine 
platelets, CD40-activated platelets showed an increased 
release of chemokine (C-X-C motif) ligand 4 (Figure IIIB in 
the online-only Data Supplement).
Platelet CD40 Modulates the Formation 
of Platelet–Leukocyte Aggregates
In the absence of platelet CD40, the formation of 
CD45+CD41+ platelet–leukocyte aggregate was significantly 
impaired (Figure 2A and 2B). In particular, lack of CD40 
on platelets attenuated platelet interactions with monocytes 
(CD11b+), dendritic cells (CD11c+), and neutrophils (Ly6G+), 
but not with T cells (CD3+; Figure 2C–2F). Cytokine levels 
were measured in the supernatants of platelet–splenocyte 
cocultures and showed a profound reduction in IL-1β lev-
els, whereas transforming growth factor-β release was unaf-
fected (Figure 2G and 2H). Of note, IL-1β released into the 
supernatant of these coculture systems seems to derive mostly 
from leukocytes as platelets alone did not secrete appreciable 
amounts of this cytokine, even on stimulation (Figure IC in 
the online-only Data Supplement). The role of platelet CD40 
in platelet–leukocyte aggregate formation was also confirmed 
in human platelets and leukocytes where activation of CD40 
increased the amount of CD45+CD41+ aggregates (Figure IIIC 
in the online-only Data Supplement).
CD40-Deficient Platelet Aggregates Show 
Impaired Leukocyte Recruitment
Because platelets are first responders in vascular injury and 
thrombosis-promoting leukocyte recruitment into inflamed 
tissues,4,42 we used an ex vivo model of collagen-induced 
Nonstandard Abbreviations and Acronyms
CD cluster of differentiation
EC endothelial cell
IL interleukin
(s)CD40L (soluble) CD40 ligand
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thrombus formation to study platelet-mediated recruitment of 
leukocytes using platelets from wild-type, Cd40l−/−, Cd40−/−, 
and P-selectin–deficient (Selp−/−) mice. In contrast to abundant 
leukocyte adhesion to thrombi consisting of Apoe−/− platelets, 
deficiency of platelet CD40L, CD40, or P-selectin resulted in 
a significant decrease of adherent leukocytes in the thrombus 
(Figure 3A and 3B). Furthermore, when thrombi from Cd40−/
−Apoe−/− platelets were treated with a blocking anti–P-selectin 
antibody, leukocyte recruitment was almost completely pre-
vented. In agreement with this, Cd40l−/−Apoe−/− thrombi treated 
with a blocking anti–P-selectin antibody or Selp−/−Apoe−/− 
thrombi treated with an anti-CD40L antibody also resulted 
in near absence of leukocyte recruitment, suggesting an addi-
tive effect (Figure 3A). Of note, platelets of all genotypes did 
not differ in the extent of thrombus formation (Figure 3C). 
Two-photon microscopy disclosed that 80% of the attracted 
leukocytes were Ly6G+ neutrophils, whereas only 20% were 
CD11b+Ly6G- monocytes (Figure 3D–3F). No differences in 
leukocyte subset distribution could be detected between the 
different groups (data not shown). These results suggest that 
thrombi dynamically recruit leukocytes (predominantly Ly6G+ 
neutrophils) to a site of injury through intercellular interactions 
that are mediated by CD40, CD40L, and P-selectin, thus poten-
tially accelerating the progression of atherosclerotic plaques.
Platelet CD40 Facilitates Platelet–
Endothelium–Leukocyte Interactions
When Cd40−/−Apoe−/− platelets were injected, they showed less 
abundant adhesion to the endothelium in vivo (Figure 4A and 
4B). Moreover, ex vivo stimulation of EC with either activated 
Apoe−/− or Cd40l−/−Apoe−/− platelets revealed that also other 
adhesion molecules, such as vascular cell adhesion molecule 
(VCAM)-1, platelet EC adhesion molecule, VE-cadherin, 
and P-selectin, were significantly decreased in the absence of 
platelet CD40 (Figure 4I).
To investigate the effects of recurrent platelet activation 
on leukocyte adhesion to the carotid artery was analyzed in 
Apoe−/− mice that were injected with activated platelets for 4 
weeks. In mice that received Cd40−/−Apoe−/− platelets, leuko-
cyte adhesion was significantly reduced (Figure 4C and 4D) 
because of a reduction in Gr1+ inflammatory monocytes and 
neutrophils (Figure 4E and 4F). In addition, immobilization of 
anti–VCAM-1-labeled microbeads was significantly reduced 
in mice injected with Cd40−/−Apoe−/− platelets (Figure 4G and 
4H), suggesting limited endothelial activation and VCAM-1 
expression as a potential cause for decreased leukocyte 
recruitment on injection of Cd40−/−Apoe−/− platelets.
To determine whether VCAM-1 and IL-1β are involved 
in platelet-induced leukocyte adhesion, we performed flow 
chamber experiments in which ECs were cultured and primed 
with either Cd40−/−Apoe−/− or Apoe−/− platelets. Subsequently, 
the ECs were incubated with anti–VCAM-1, anti–IL-1β, or 
control antibodies followed by perfusion of leukocytes and 
their adhesion was monitored. Supporting the in vivo results, 
priming with CD40-deficient platelets limited platelet-induced 
leukocyte interactions with ECs (Figure 4J). Moreover, 
blocking either VCAM-1 or IL-1β potently reduced platelet-
induced leukocyte adhesion indicating a prominent role for 
these mediators in platelet-modulated leukocyte extravasation 
(Figure 4K and 4L). Interestingly, when priming with CD40-
deficient platelets, anti–VCAM-1 antibody treatment even 
further limited leukocyte adhesion (Figure 4K).
Platelet CD40 Promotes Atherosclerosis Progression
To address the role of platelet CD40 in atherosclerosis in vivo, 
injections of activated platelets in Apoe−/− mice started at the 
A
B C
Figure 1. Cluster of differentiation 40 (CD40)–
deficient platelets exhibit normal platelet activation. 
A and B, Platelet aggregation measured by multiple 
electrode platelet aggregometry (Multiplate). Plate-
let aggregation was triggered by collagen  
(4 µg/mL) or ADP (4 µmol/L) in hirudin-anticoagu-
lated blood from Apoe−/− or Cd40−/−Apoe−/− mice. 
Two independent aggregation curves (red and blue) 
were obtained by duplicate sensors located in each 
test cell. A, Representative measurements of col-
lagen-triggered aggregation. B, Mean values of the 
2 determinations are expressed as area under the 
curve (n=5). C, Chemokine (C-X-C motif) ligand 4 
levels measured by ELISA in the supernatants from 
thrombin-activated (0.5 nmol/L, 15 min) platelets 
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age of 17 weeks (baseline) and were repeated every fifth day for 
12 weeks. At study end, plasma cholesterol levels of all groups 
had increased when compared with plasma cholesterol levels of 
the baseline group, but no differences were observed between 
the platelet- and vehicle-injected animals (baseline, 318.5±53.2 
mg/dL versus Apoe−/− 523.7±27.6 mg/dL versus Cd40−/−Apoe−/− 
532.3±31.2 mg/dL versus vehicle 469.7±40.8 mg/dL; n=11). 
After the injection, blood leukocyte populations were analyzed 
by flow cytometry. No differences in total leukocytes (CD45+), 
monocytes (CD11b+), T cells (CD3+), or B cells (B220+) were 
observed. However, a relative decrease in the amount of Ly6G+ 
neutrophils was detected in the animals injected with Cd40−/− 
Apoe−/− platelets (Figure IV in the online-only Data Supplement).
As expected, Apoe−/− mice injected with activated Apoe−/− 
platelets displayed a 2-fold increase in plaque area in the aortic 
arch and its major branch points when compared with vehicle-
treated animals (Figure 5A and 5B). Of note, the proathero-
genic effect of platelet-infusion was irrespective of the Apoe 
genotype (Figure V in the online-only Data Supplement). 
Remarkably, this platelet-induced acceleration of atherosclero-
sis was prevented in Apoe−/− mice injected with Cd40−/−Apoe−/− 
platelets. Analysis of plaque size in the ascending aorta cor-
roborated the central role of CD40 in platelet-induced plaque 
progression (Figure 5C).
The increase in plaque size in Apoe−/− animals injected 
with Apoe−/− platelets was associated with more inflamma-
tory and advanced fibrotic plaque characteristics, as reflected 
by the high amount of fibrous cap atheroma (as classified by 
Virmani et al43) in this experimental group (Figure 5D–5E). 
Apoe−/− mice injected with Cd40−/−Apoe−/− platelets only dis-
played an initial plaque phenotypes corresponding to intimal 
xanthomas, characterized by focal accumulations of foam cells 
and pathological intimal thickening where true necrosis is not 
yet apparent. This initial lesion phenotype was reflected by 
the reduction in collagen and lipid core size in the plaques of 
Apoe−/− mice injected with Cd40−/−Apoe−/− platelets (Figure 5F 
and 5G). Furthermore, plaques of mice injected with Cd40−/−
Apoe−/− platelets exhibited a significant decreased number of 
Mac-3+ macrophages, Ly6G+ neutrophils, and a trend toward a 
decreased T-cell content and reduced expression of caspase-3 
(Figure 5H–5K). Overall, these data clearly demonstrate that 






Figure 2. Deficiency of platelet cluster of differentiation 40 (CD40) obstructs platelet–leukocyte aggregation (PLA). Platelet–leukocyte 
aggregation through coincubation of activated platelets isolated from Apoe−/− or Cd40−/−Apoe−/− mice cultured with Apoe−/− splenocytes, 
measured by flow cytometry. PLA formation is expressed relative to Apoe−/− platelets. A, Platelets conjugated to CD45+ leukocytes. B, In 
vitro 2-photon microscopic detection of PLA from Apoe−/− platelets cultured with Apoe−/− splenocytes. Overview (left) and higher magni-
fication (right) of the indicated area. Leukocytes were labeled with DAPI (4’,6-diamidino-2-phenylindole; blue) and platelets with calcein 
(green). Scale bar, 5 µm. C–F, Flow cytometry analysis of CD41+ platelets conjugated with (C) CD11b+ monocytes, (D) CD11c+ dendritic 
cells, (E) Ly6G+ neutrophils, or (F) CD3+ T cells (n=6 for A, C–F). G, Transforming growth factor (TGF)-β and (H) interleukin (IL)-1β levels 
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Discussion
The capacity of platelets to promote inflammation is increas-
ingly recognized, but the full potential of the platelet as 
immune cell is still enigmatic. Here, we identified platelet-
CD40 as an important regulator of inflammatory processes 
that promote atherosclerosis.
One of the mechanisms how platelets exert inflammatory 
actions is through the heterotypic interaction with different 
immune cells promoting their recruitment and activation.44 
Platelets can form these heterotypic complexes via membrane 
receptors such as P-selectin, CD40L, and αIIbβ3 that bind 
PSGL, CD40, and CD11b, respectively, on the leukocyte.2,36 
Elevated levels of circulating platelet–leukocyte aggregates 
have been reported in several cardiovascular diseases and sug-
gested to contribute to disease pathology. Increased levels of 
platelet–monocyte aggregates are found in patients with acute 
myocardial infarction and can therefore been seen as an early 
marker of acute myocardial infarction.45 Selectively blocking 
platelet–monocyte interactions is currently under evaluation 
in clinical trials. Inclacumab, an anti-P-selectin antibody, 
hinders the formation of platelet–monocyte aggregates and 
thereby prevents the inflammatory burst of these interac-
tions.46 Likewise, acute coronary syndromes are characterized 
by intense neutrophil activation. Recent studies report that this 
activation is induced by platelet–P selectin interactions induc-
ing complete myeloperoxidase depletion in neutrophils.47 
Furthermore, in vitro studies revealed that platelets control the 
recruitment, activation, differentiation, and cytokine produc-
tion of different CD4+ T-cell subsets.48 We recently showed 
in vivo that platelet CD40L mediates the reduction of cir-
culating Treg cells, thereby promoting the development of 
atherosclerosis.36
When injecting platelets deficient for CD40, no differences 
in counts of total leukocyte, monocytes, T cell, or B cells were 
noticed, whereas a relative decrease in the amount of Ly6G+ 
neutrophils when compared with wild-type platelet-injected 
mice was observed. Until now, we have no clear explana-
tion how the relative reduction in circulating neutrophils is 
induced. It is conceivable that injection of thrombin-activated 




Figure 3. Platelet cluster of differentiation 40 (CD40) recruits leukocytes into thrombi. Leukocyte recruitment into collagen-induced, 
thrombin-activated, Apoe−/−, Selp−/−Apoe−/−, Cd40−/−Apoe−/−, and Cd40l−/−Apoe−/− platelet aggregates. A, Numbers of leukocytes adhering 
to the platelet thrombi per field (n=6, *P<0.05). Depicted is the average of 25 counted microscopic fields. B, Representative microscopic 
images. Scale bar, 20 µm. C, Thrombus density expressed as relative platelet-covered area. Two-photon microscopic analysis of percent-
age of (D) CD11b+Ly6G+ and (E) CD11b+Ly6G- leukocytes recruited to the thrombi generated from platelets of the respective mice.  
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inflammatory stimuli than injection of thrombin-activated 
wild-type platelets, resulting in lower number of neutrophils 
in the circulation. We assume that the systemic reduction in 
neutrophils may affect their recruitment rate. However, this 
effect may play only a minor role in total leukocyte recruit-
ment, whereas the predominant effect of platelet CD40 on leu-
kocyte recruitment is most likely mediated via EC activation.
Here, we observed that platelet CD40 can also bind leu-
kocytes and form platelet–leukocyte aggregates. Platelet CD40 
particularly bound neutrophils and monocytes, dendritic cells, 
but not T cells. CD40-dependent platelet–leukocyte cross talk 
promoted the release of IL-1β, a major mediator of platelet-
induced activation of the endothelium by inducing endothelial 
adhesion molecule expression (VCAM-1 and intercellular adhe-
sion molecule–1) and cytokine production (IL-6 and IL-8).49,50 
In addition, we show that platelet CD40 has an important role 
in promoting endothelial activation and attracting more mono-
cytes and neutrophils toward the site of inflammation.
Not only single platelets stimulate inflammation but 
also platelet aggregates are considered to be proinflam-
matory. During the time course of atherosclerosis, platelet 
aggregates continuously form on the endothelium. Because 
these aggregates consist of activated platelets releasing their 
granule content and inflammatory mediators, it is conceiv-
able that this instigated inflammatory milieu enhances leuko-
cyte recruitment, and thereby aggravates atherosclerosis. We 
here reveal that recruitment of leukocytes into platelet aggre-
gates is strongly mediated by platelet CD40, as well as by 
platelet CD40L and P-selectin. Autopsy studies suggest that 
during life, the vasculature undergoes numerous plaque rup-
tures with consequent (nonocclusive) thrombus formation. 
These thrombi are resolved without causing any symptoms.42 
Because frequently occurring (silent) thrombi induce rapid 
progression of atherosclerosis, we consider CD40-mediated 
leukocyte recruitment into thrombi as an another important 
mechanism in the repertoire of platelet immunity.42
Unlike its potential to induce inflammation, we could not 
find a role for platelet CD40 in platelet–platelet interactions 
when the major platelet receptors GPVI (convulxin), puri-
nergic receptor class 2, subclass Y1/Y2 (ADP), and protease-
activated receptor-3/4 (thrombin) were activated. These results 
are in contrast with the previous report by Inwald et al,13 who 
reported that ligation of platelet CD40 caused increased 
P-selectin expression and the classical morphological changes 
associated with platelet activation, yet did not result in Ca2+ 









Figure 4. Platelet cluster of differentiation 40 (CD40) deficiency reduces endothelial activation and neutrophil recruitment. A and B, Intra-
vital microscopic analysis of platelet adhesion to endothelium in the carotid artery of Apoe−/− mice treated with tumor necrosis factor 
(TNF)-α (500 ng, IP) for 30 min and subsequently infused with thrombin-activated platelets (0.5 nmol/L, 15 min; 3×107/20 g) isolated from 
Apoe−/− or Cd40−/−Apoe−/− mice (n=4). C–H, Intravital microscopy of carotid arteries from Apoe−/− mice fed a Western-type diet for 4 wk 
and injected with Apoe−/− or Cd40−/−Apoe−/− platelets every fifth day. C and D, Interactions of leukocytes with the carotid artery visualized 
by rhodamine injection. E and F, Inflammatory monocytes and neutrophils were visualized with an antibody to Gr1. G and H, Luminal 
arrest of fluorescent beads conjugated with antibody to vascular cell adhesion molecule (VCAM)-1 (n=6; scale bar, 100 µm for B, D, F, 
and H). I, Quantitative polymerase chain reaction to determine mRNA expression of various adhesion molecules and inflammatory media-
tors in endothelial cells (SVEC4-10) coincubated for 12 h with thrombin-activated platelets from Apoe−/− or Cd40−/−Apoe−/− mice. Data 
are expressed relative to the control group (n=4). J, Confluent endothelial cells (SVEC4-10), stimulated with TNF-α (10 ng/mL; 4 h) were 
exposed in flow chambers to perfusion with thrombin-activated platelets from Apoe−/− or Cd40−/−Apoe−/− mice for 20 min followed by per-
fusion with calcein-labeled leukocytes (RAW 264.7). Adherent cells per field of view were counted. Similar leukocyte adhesion flow cham-
ber assays performed in the presence of (K) anti-VCAM and (L) anti–IL-1β antibodies or the respective isotype-matched controls (n=4, 8 
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used a recombinant form of sCD40L to induce platelet activa-
tion, whereas we used thrombin-induced platelet activation.13 
Recently, we have identified that CD40L and CD40 have, in 
part, different roles in collagen-induced platelet aggregation 
and thrombus growth.39 Although CD40 deficiency did impair 










Figure 5. Platelet cluster of differentiation 40 (CD40) expression mediates platelet-induced atherosclerosis. Seventeen-week-old Apoe−/− 
mice (n=11) were injected for 12 wk with thrombin-activated Apoe−/− platelets, Cd40−/−Apoe−/− platelets, or vehicle and euthanized at the 
age of 29 wk. Baseline animals (17 wk) were included. A, Plaque area (μm2) in the aortic arch and main branch points (n=11). B, Repre-
sentative longitudinal images of the aortic arch and branch points (hematoxylin-eosin [HE] staining). C, Plaque area (μm2) in the aortic 
root (n=5). D, Lesions of the aortic arch and branch points were classified according to Virmani guidelines. E, Representative longitudinal 
images of the brachiocephalic artery (HE staining). F–K, Histological analysis of the aortic arch and its major branch points. F, Lipid core 
content measured by Oil Red O. G, Plaque collagen content measured as Sirius red+ staining. H, Absolute numbers of Mac-3+ macro-
phages per section. I, Relative frequency of Ly6G+ neutrophils. J, Percentage of CD3+ T cells. K, Cleaved caspase-3 staining was graded 
from 0 (not present) to 3 (highly present; n=11 for F–K). Scale bar, 200 µm; *P<0.05. FCA indicates fibrous cap atheroma; IX, intimal xan-
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material or on collagen, CD40 only had a modest role in throm-
bus formation, whereas platelet CD40L is important in colla-
gen-induced thrombus formation and growth.39 Still, platelet 
CD40 signaling remains only poorly understood. Intracellular 
communication may involve the CD40-tumor necrosis fac-
tor–associated factor signaling pathway, as is known in leu-
kocytes.19 Of note, it was reported that sCD40L exacerbates 
platelet activation and aggregation through a CD40-dependent 
tumor necrosis factor–associated factor 2 mechanism.51
Taken together, inhibition of platelet CD40 represents an 
attractive therapeutic target. Because antibody treatment of its 
counterpart CD40L caused thromboembolic events, clinical tri-
als were halted.38,52 Hence, antagonizing CD40 provides a viable 
alternative offering many advantages. During the past decade, 
researchers have aimed to develop CD40 as a treatment for cancer 
because of its inflammatory capacity and overexpression in certain 
tumors. The recently developed experimental CD40-antagonizing 
antibody is currently extensively tested in cancer research where 
it is thought to block proliferation of CD40+ malignant cells.53 
A safety trial with another anti–CD40-antagonizing antibody, 
ch5D12, showed a reduction in inflammatory activity in biopsies 
of patients having patients with Crohn disease.54
With the results of the current study, we provide a novel 
therapeutic target in cardiovascular medicine acting at the 
critical interface between inflammation, thrombosis, and ath-
erosclerosis. Selectively blocking platelet CD40 will impede 
platelet-induced leukocyte recruitment and endothelium acti-
vation eventually reducing formation and complication of 
atherosclerosis.
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Besides their obvious thrombogenic function in vascular pathologies, platelets can also initiate and sustain inflammatory processes, predominantly 
by triggering leukocyte recruitment toward the core of the inflammation. Cluster of differentiation 40 (CD40) and its ligand CD40L, present on not 
only many immune cells but also on platelets, are well-known costimulatory molecules that mediate both thrombotic and immune reactions. In this 
study, we investigated the inflammatory power of platelet-specific expression of CD40, an integral membrane protein of the tumor necrosis factor 
receptor family. Our data reveal an important role for platelet CD40 in the progression of atherosclerosis. Platelet CD40 amplifies immune responses 
by activating leukocytes and endothelial cells, thereby stimulating the recruitment of inflammatory cells toward the atherosclerotic plaque. There-
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